Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

CFO Appointment

15 Oct 2007 09:23

Seeing Machines Limited15 October 2007 15 October 2007 Seeing Machines Limited ("Seeing Machines" or the "Company") SEEING MACHINES ANNOUNCES CFO APPOINTMENT Seeing Machines (AIM:SEE), a leading developer of advanced computer basedimaging software systems, announces today the appointment of Mr ChristopherMcKee as Chief Financial Officer, commencing on 19 November 2007. Mr McKee holdsMBA and B.Comm qualifications and has been a Member of the Institute ofChartered Accountants in Australia since 1990. Prior to joining Seeing Machines Mr McKee was Asean Regional FinancialController for Hyder Consulting Pty Limited, the Australian subsidiary of HyderConsulting plc a UK listed engineering consulting company (HYC.L). In this rolehe was responsible for key financial aspects of the group's Asean operationsthrough Australia, New Zealand, Vietnam and Singapore (with Australian turnoverin the 2007 year of A$90 million and employing over 600 staff) and reportinginto the UK listed parent company. Prior to Hyder Consulting P/L Mr McKee had awide range of industry experience, including accommodation services, largehotels and aged care facilities, and roles with international charteredaccounting firms Price Waterhouse and Priestly and Morris. Dr Nick Cerneaz, CEO of Seeing Machines commented: "The addition of Chris to theSeeing Machines team adds a depth of experience and knowledge that greatlystrengthens our efforts to drive the Company forward. His experience as both afinancial and strategic business manager through a number of senior and verycommercially focussed roles across international markets, coupled with hisbackground of Chartered Accountancy and an MBA bring significant new skills tothe Company's management team. We are very pleased to welcome Chris to SeeingMachines, especially at this time as we continue to progress thecommercialization of our technology portfolio." Further information about Seeing Machines can be obtained from the companywebsite www.seeingmachines.com. --- ENDS --- Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Peter Ward Justine Howarth Chris Caldwell Erica Nelson+61 (0) 2 6125 6501 +44 (0) 20 7190 7000 +44 (0) 20 7851 7480www.seeingmachines.com Notes to editors: About Seeing Machines Seeing Machines is an award winning Technology Company which focuses on visionbased human machine interfaces. Formed in 2000 in Canberra, Australia, SeeingMachines' purpose is to commercialise its computer-vision across a range ofindustries and applications. Seeing Machines deliver advanced computer vision solutions for researches anddevelopers in human factors, transportation safety, computer human interaction,robotics, medical research and psychology. The flagship product faceLAB(R)provides an automated and contact-free gaze and head tracking technology, itsolves the problem of observing human behaviour naturally, non-intrusively andwith a high degree of accuracy and usability. Building on these unique facetracking and pupil measurement and monitoring capabilities, the TrueFieldAnalyzer(R) is a development undertaken by Seeing Machines in partnership withcolleagues from the Research School of Biological Sciences (RSBS) at theAustralian National University (ANU). The TrueField Analyzer(R) offers a new objective method to help doctors diagnoseand manage a range of eye diseases including glaucoma, age related maculardegeneration and diabetic retinopathy. Glaucoma affects about 2-3% of thepopulation over 40 years of age and is a leading source of blindness. Unlikemost other devices available to the clinician the TrueField Analyzer is acompletely objective test and it is quick and easy for patients and techniciansalike. The device measures both eyes concurrently and due to the reliabilitythat arises from the objective nature of the test, it has the potential tobecome a new standard in the measurement of visual field defects and thus in thediagnosis and management of disease such as glaucoma. More generally Seeing Machines' computer vision systems are able to measure theorientation and position of a human head, estimate eye-gaze direction, detecteye blinks and track other facial features. This functionality is achievedentirely though visual means, using video cameras connected to advanced imageprocessing software, with no attachments required on the subject. Products suchas faceLAB(R) are designed to allow human factors researchers and designers toassess the interaction of an operator in an environment and this findsapplication in designing operator environments, such as cockpits for cars,trucks, trains, and aeroplanes for instance, and other industrial designapplications, as well as medical and psychological research situations. Thetechnology also has application in monitoring automobile drivers and if itdetects drowsiness or that the driver is distracted and their attention has beendiverted from the road, an alarm can be raised to alert the driver to eitherpull over and rest in the case of drowsiness or to pay more attention to theroad. The systems work in real-time, enabling the behaviour of subjects to be trackedin real-time. This technology is paving the way in promoting safer drivingconditions and works to enhance the driving experience and to eliminateaccidents caused through driver drowsiness or distraction. There are many different sectors that can benefit from this revolutionarysoftware, for which it has been developed, including: automotive; academicresearch; medicine/healthcare; defence; autostereoscopy (next generationdisplays); sport; and games. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Dec 20237:00 amRNSSeeing Machines announces US$30M European OEM win
13th Dec 20238:02 amRNSSeeing Machines welcomes U.S. NHTSA announcement
12th Dec 20237:00 amRNSSeeing Machines Wins Prestigious Road Safety Award
29th Nov 20237:57 amRNSResult of AGM
24th Nov 20237:00 amRNSAGM – reminder and correction of login details
8th Nov 20237:00 amRNS16th Automotive program awarded & Q1 FY2024 KPIs
6th Nov 202311:26 amRNSDirector/PDMR Shareholding
31st Oct 202311:50 amRNSDirector/PDMR Shareholding
31st Oct 20237:00 amRNSNotice of AGM
27th Oct 20237:19 amRNSDirector/PDMR Shareholding
27th Oct 20237:13 amRNSDirector/PDMR Shareholding
25th Oct 20237:55 amRNSDirector/PDMR Shareholding
25th Oct 20237:00 amRNSBoard Changes
20th Oct 20239:30 amRNSDirector/PDMR Shareholding
20th Oct 20239:21 amRNSDirector/PDMR Shareholding
19th Oct 20238:47 amRNSDirector/PDMR Shareholding
18th Oct 202310:06 amRNSDirector/PDMR Shareholding
17th Oct 20239:41 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSYear End Results – FY2023
16th Oct 20237:00 amRNSDevelopment of aviation fatigue detection solution
14th Sep 20237:00 amRNSNotice of Full Year Results 2023
7th Sep 20235:31 pmRNSDirector/PDMR Shareholding
22nd Aug 20237:00 amRNSFY2023 Trading Update & Q4 KPIs
18th Jul 20237:30 amRNSDirector/PDMR Shareholding
30th Jun 20237:00 amRNSDirector/PDMR Shareholding
30th Jun 20237:00 amRNSCEO Incentive Plan
28th Jun 20231:44 pmRNSDirector/PDMR Shareholding
28th Jun 20237:00 amRNSDirector/PDMR Shareholding
26th Jun 202311:38 amRNSDirector/PDMR Shareholding
23rd Jun 20238:55 amRNSDirector/PDMR Shareholding
20th Jun 20237:30 amRNSCollaboration with synthetic data specialist
19th Jun 20238:00 amRNSSeeing Machines to attend Stifel Tech Conference
25th May 20239:53 amRNSDirector/PDMR Shareholding
22nd May 20239:46 amRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSExclusive Agreement Signed with Collins Aerospace
4th May 20237:00 amRNSKey Performance Indicators Q3 FY2023
17th Apr 20239:29 amRNSDirector/PDMR Shareholding
13th Apr 202312:36 pmRNSDirector/PDMR Shareholding
11th Apr 202311:15 amRNSPDMR Shareholding
6th Apr 20232:45 pmRNSDirector/PDMR Shareholding
5th Apr 20239:08 amRNSPDMR Shareholding
31st Mar 202312:26 pmRNSPDMR Shareholding
29th Mar 202311:55 amRNSDirector/PDMR Shareholding
28th Mar 202311:28 amRNSPDMR Shareholding
27th Mar 202310:12 amRNSDirector/PDMR Shareholding
27th Mar 202310:07 amRNSDirector/PDMR Shareholding
24th Mar 202311:56 amRNSPDMR Shareholding
24th Mar 20238:59 amRNSDirector/PDMR Shareholding
22nd Mar 20239:16 amRNSPDMR Shareholding
17th Mar 20239:03 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.